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Abstract 
Cognitive impairments are considered a core feature of schizophrenia. Nicotine has been 
suggested to have an effect on cognition in individuals with schizophrenia and in the general 
population. Since smoking status is seldom controlled for in cognitive research studies 
understanding the contribution of nicotine dependence is a potentially important issue for data 
interpretation. Thus, the current study examined whether smoking status has a differential 
association with cognition and regional cortical thickness in 71 patients and 63 nonpsychiatric 
control participants. Cognition was measured with the MATRICS Consensus Cognitive Battery 
(MCCB) and social cognition was measured with the Faux Pas and Reading the Mind in the Eye 
tasks. The Vocabulary and Matrix Reasoning subtests of the Wechsler Abbreviated Scale of 
Intelligence (WASI) and Wide Range Achievement Test (WRAT-4) were used to assess general 
intelligence (IQ) and premorbid functioning, respectively. Cortical thickness was measured with 
a high-resolution 3-Tesla MR whole body scanner. Results revealed that patients (relative to 
controls) and smokers (as compared to nonsmokers) showed impairments on all cognitive 
measures (e.g., attention, processing speed, working memory, social cognition, etc.). 
Neuroimaging results indicated widespread cortical thinning among patients as compared to 
controls. However, patient smokers and control nonsmokers had similar cortical thickness 
patterns in the left parahippocampal gyrus and bilateral medial orbitofrontal gyri. The findings 
suggest that smoking status should be taken into consideration in cognitive research given that 
smoking status may confound overall results. 
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Introduction 
Schizophrenia is a chronic debilitating disorder characterized by an inability to discern 
reality and has a lifetime prevalence of approximately 4.0 per 1000 (McGrath, Saha, Chant, & 
Welham, 2008). In 2004, an estimated 234,305 individuals living in Canada with this illness led 
to an approximate cost of $6.85 billion dollars as a result of the direct impact on the healthcare 
system, the fact that fewer than 10% were employed, and the associated morbidity and mortality 
rates (Goeree, Farahati, Burke, Blackhouse, O’Reilly, Pyne & Tarride, 2005; Marwaha & 
Johnson, 2004). Schizophrenia not only places great demands on the economic system, but it is 
also a disabling condition for sufferers. In fact, this disorder is the most debilitating mental 
illness, which in part fuels the considerable amount of research interest it continues to receive. 
The symptoms those with schizophrenia experience can include delusions and/or 
hallucinations; they may also lack motivation or drive to accomplish goals; as well as suffer a 
reduction in their ability to experience and recognize emotional expression (Diagnostic and 
Statistical Manual of Mental Disorders (DSM–5, 2013). There is also evidence to suggest a direct 
link between poor performance on neurocognitive measures and impaired social functioning 
(Niendam, Bearden, Johnson, McKinley, Loewy, O'Brien, Nuechterlein, Green, & Cannon, 
2006). Indeed, cognitive impairment is a core feature of the disorder found among 70-75% of 
this population (Heinrichs, 2005; Heinrichs & Zakzanis, 1998) and is predictive of functional 
outcome (e.g., social, occupational, and living status; Green, Kern, & Heaton, 2004; Heinrichs, 
Goldberg, Miles & McDermid Vaz, 2008). However, although recognized as a core feature, it is 
neither included in diagnosis as part of the previous DSM-IV-TR nor the current DSM-5. 
Currently, more research is needed to enhance clinical utility in distinguishing the specific 
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cognitive deficits of schizophrenia from those of other psychiatric illnesses (Barch, Bustillo, 
Gaebel, Gur, Heckers, Malaspina, Owen, Schultz, Tandon, Tsuang, Van Os, & Carpenter, 2013).  
When compared with healthy controls, individuals with schizophrenia demonstrate 
impairments on tests of selective and sustained attention, visuospatial and working memory, 
deficits in executive function as well as other cognitive impairments (Dickinson & Harvey, 2009; 
Heinrichs & Zakzanis, 1998). Several research studies have identified the greatest impairments 
being those of executive function, speed of processing, and attention (Dickinson & Harvey, 
2009; Orellana & Slachevsky, 2013). The degree of cognitive impairments may result from 
progressive changes in the brain of those afflicted with the illness over the course of 
development leading to structural abnormalities (Andreasen, 2010).  
This paper will first review the neuroimaging evidence of structural abnormalities that 
may be linked to cognitive impairments and symptoms of schizophrenia. Secondly, the role of 
nicotine in targeting illness-specific cognitive impairments in schizophrenia will be discussed. 
This review of the literature will provide an understanding of the rationale for the current study.  
Structural Abnormalities 
There are numerous disease-related structural abnormalities in schizophrenia. Findings of 
enlarged cerebral ventricles have been frequently replicated in imaging studies and are 
characteristic of the illness, although normal variation in enlargements can be found among 
healthy populations (reviewed in Jaaro-Peled, Ayhan, Pletnikov, & Sawa, 2010). An increase in 
ventricular size is associated with decrease cortical volume (Jaaro-Peled et al., 2010). 
Consequently, there is consistent research evidence to support findings that neuroanatomical 
abnormalities include a reduction in cortical thickness volume and density in several brain areas, 
which may be responsible for cognitive deficits seen in patients (Mueser & McGurk, 2004; for 
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review see Jaaro-Peled et al., 2010 and Honea, Meyer-Lindenberg, Hobbs, Pezawas, Mattay, 
Egan, Verchinski, Passingham, Weinberger, & Callicott, 2008). 
Cortical thickness is representative of densely arranged neurons and glial cells, synaptic 
spines, and axons (Garey, 2010). Postmortem studies of individuals with schizophrenia show 
decreased overall brain volume due to reduced size and amount of neurons, dendritic 
arborization, synaptic spines and interneuronal neuropil in certain brain regions (e.g., frontal and 
temporal lobes; Garey, 2010; Oertel-Knöchel, Knöchel, Rotarska-Jagiela, Reinke, Prvulovic, 
Haenschel, Hampel, & Linden, 2013; Orellana & Slachevsky, 2013). The reduction in cortical 
volume may be due to apoptosis or reduced synaptic connections in local brain regions 
(Goldman, Pezawas, Doz, Mattay, Fischl, Verchinski, Chen, Weinberger, Meyer-Lindenberg, 
2009).  
Converging evidence shows that there is reduced cortical thickness within the frontal 
lobes (particularly the prefrontal cortex), cingulate gyrus, medial temporal lobe structures 
(hippocampus, amygdala, entorhinal and parahippocampal cortex), superior and middle temporal 
gyri, and subcortical structures (Ho, Andreasen, Nopoulos, Arndt, Magnotta, & Flaum, 2003; 
Mjellem & Kringlen, 2001; Mueser & McGurk, 2004; Oertel-Knöchel et al., 2013). Ehrlich and 
colleagues (2012) found reductions in cortical thickness in both hemispheres among patients, 
such that the frontal, temporal, inferior parietal, and occipital lobes were areas commonly 
affected.  
It has also been reported that the most significant reduction in cortical thickness among 
individuals with schizophrenia is found within the lateral surface of the temporal lobe and frontal 
lobe (more specifically reduced thickness in bilateral caudal middle frontal gyrus, inferior and 
superior frontal gyri; Goldman et al., 2009). Interestingly, the most pronounced cognitive deficits 
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commonly found amongst this clinical population are those affected by frontal and temporal lobe 
abnormalities (Cobia, Smith, Wang, & Csernansky, 2012; Ragland, Yoon, Minzenberg, & 
Carter, 2007; Reichenberg, & Harvey, 2007). The possible link between structural abnormalities 
and both cognitive impairments and symptoms of schizophrenia will be discussed below. 
Neuroanatomical abnormalities are reported to have a genetic link and are possible 
vulnerability markers as unaffected first-degree relatives of individuals with schizophrenia also 
show brain abnormalities (Chan, McAlonan, & Gong, 2011; Ho et al, 2003; Jaaro-Peled et al., 
2010). Among unaffected first-degree relatives, however, abnormalities tend to be less severe 
than among individuals with the illness. Research studies conducted with unaffected first-degree 
relatives largely mirror studies of patient population. There are reports of reduced cortical 
thickness in frontal, temporal and limbic areas to name a few (Oertel-Knöchel et al., 2013). 
However, relatives tend to show cortical abnormalities at younger ages and these abnormalities 
tend to disappear by age 20 years (Gogtay Greenstein, Lenane, Clasen, Sharp, Gochman, Butler, 
Evans, & Rapoport, 2007). Taken together, brain structural abnormalities have been found in 
individuals with schizophrenia and their first-degree relatives, and these abnormalities may be 
involved in the pathophysiology of the illness. 
Linking Structure to Function 
Abnormalities found in the frontal lobe have been linked to several deficits. Specifically, 
diminished cortical white matter density of the frontal lobe is found among individuals with 
schizophrenia as compared to healthy controls, which may be due to neurodevelopmental 
abnormalities that led to an arrest in myelination or cortico-cortical connections (Dickinson & 
Harvey, 2009; Ho et al, 2003; Jaaro-Peled, 2010). Reduced volumes in the dorsolateral prefrontal 
cortex and medial frontal cortex (including the anterior cingulate cortex) have been observed 
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(see Lesh, Niendam, Minzenberg, & Carter, 2011 for a review). Volume reductions in the 
anterior cingulate cortex and dorsolateral prefrontal cortex as well as compromised white matter 
tracts that allow communication between brain regions may be linked to the cognitive 
impairments in schizophrenia including episodic and working memory, attention, and processing 
speed (Dickinson & Harvey, 2009; Lesh, Niendam, Minzenberg, & Carter, 2011).  
Individuals with schizophrenia tend to also have impairments in social cognition. For 
example, in tasks that require empathic reflections or the processing of social information, 
patients tend to show decreased activation in the left prefrontal cortex and medial orbitofrontal 
gyrus (Hynes, Baird, & Grafton, 2006; Mueser & McGurk, 2004). The frontal lobe is also 
important for processing verbal learning, a measure of learning and memory, which is positively 
correlated with executive function in schizophrenia (Fossati, Amar, Raoux, Ergis, & Allilaire, 
1999; Hartberg, Lawyer, Nyman, Jönsson, Haukvik, Saetre, Bjerkan, Andreasen, Hall & Agartz, 
2010). In both individuals with schizophrenia and healthy controls, verbal learning is linked to 
superior and middle fontal gyri such that poor performance is associated with reduced thickness 
in these areas (Hartberg et al., 2010).  
Progressive reductions of white matter connectivity in frontal lobe regions (i.e., 
orbitofrontal and anterior cingulate cortex) have also been linked to greater severity of negative 
symptoms in patients and decreased executive functioning (Ho et al., 2003; Orellana & 
Slachevsky, 2013). Specifically, deficits in abstract reasoning, planning, problem solving, as well 
as impairments in social cognition are commonly seen in individuals with schizophrenia 
(Orellana & Slachevsky, 2013). The dorsolateral prefrontal cortex and the anterior cingulate 
cortex, in particular, are reported to be involved in executive functioning (Minzenberg, Laird, 
Thelen, Carter, & Glahn, 2009; Snitz, MacDonald, Cohen, Cho, Becker, & Carter, 2005). Weiss 
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and colleagues (2003) found activation in the inferior frontal cortex as well as anterior cingulate 
during a functional magnetic resonance imaging (fMRI) study of the Stroop task, another 
measure of executive functioning. Furthermore, these authors found bilateral activation within 
the prefrontal cortex of patients, while healthy controls showed activation only in the left 
hemisphere. This finding suggests that patients may recruit more cortical areas to complete the 
same cognitive task as healthy controls. 
Thus far the discussion has centered on frontal lobe abnormalities and their link to 
cognitive dysfunction (e.g., impairments in processing social information, deficits in learning 
and memory, and executive function) among individuals with schizophrenia. Research evidence 
suggests, however, that structural abnormalities are most pronounced in both frontal and 
temporal brain regions (Goldman et al., 2009; Oertel-Knöchel et al., 2013). There is also some 
overlap between these structures and their relationship to symptom severity, verbal learning and 
processing, and executive functioning (Hartberg et al., 2010). 
In particular, gray matter reductions in the left middle temporal gyrus and bilateral 
inferior temporal gyrus may be involved in semantic memory and language processing in 
individuals at chronic stages of the disease (Nestor, Onitsuka, Gurrera, Niznikiewicz, Frumin, 
Shenton, & McCarley, 2007). With respect to symptoms, while frontal regions are involved in 
negative symptoms, the temporal lobes may be implicated in positive symptoms (Oertel-Knöchel 
et al., 2013). For example, symptoms such as hallucinations tend to be related to left superior 
temporal cortex thinning in both patients and unaffected first-degree relatives (Flaum et al., 
1995; Oertel-Knöchel et al., 2013). Furthermore, there is a link between the severity of illness, 
more specifically thought disorders and auditory hallucinations, and reduced volume of the left 
superior temporal gyrus (see Sun, Maller, Guo, & Fitzgerald, 2009 for review).  
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Despite the focus on the role of the frontal and temporal lobes in cognitive dysfunction 
among people with schizophrenia, it is also important to recognize the functional connection of 
other brain structures in this illness. For instance, limbic structures (e.g., hippocampus, 
parahippocampal gyrus and amygdala) also play an important role in memory and social 
cognition (Ehrlich et al., 2012; Mueser & McGurk, 2004). In fact, studies have reported illness-
related reduction in volume of structures within fronto-temporolimbic regions (Mjellem & 
Kringlen, 2001; Glahn, Laird, Ellison-Wright, Thelen, Robinson, Lancaster, Bullmore, & Fox, 
2008). In patients, hippocampal volume is correlated with verbal working memory and 
immediate story recall, particularly within the left hemisphere (Ehrlich et al., 2012). 
There is also evidence to suggest that problems with myelination in the prefrontal cortex, 
fronto-temporal and fronto-parietal tracts may explain disruption in connectivity between 
structures, which may be related to cognitive impairments and symptomatology of the illness 
(Orellana & Slachevsky, 2013). Functional neuroimaging studies have emerged that lend support 
for disruption in neural circuits (Mueser & McGurk, 2004; Orellana & Slachevsky, 2013). This 
finding supports the view that multiple rather than single brain regions are involved in the 
widespread cognitive impairments of schizophrenia. Temporal and cerebellar regions are 
functionally connected to the prefrontal cortex and patients show reduced volume in the fronto-
temporo-cerebellar network; further, studies have shown reduced activation in this network while 
patients complete the Wisconsin Card Sorting Task, a measure of executive function 
(Riehemann, Volz, Stützer, Smesny, Gaser, & Sauer, 2001; Kašpárek, Mareček, Schwarz, 
Přikryl, Vaníček, Mikl, & Češková, 2010).  
Therefore, although studies generally show reductions in cortical thickness mainly in 
prefrontal and temporal regions and the possible link to cognitive impairment using fMRI, the 
 
 
  
8 
evidence supports the interconnectedness of several brain areas (e.g., limbic structures, auditory 
cortices, and cerebellar areas) to carry out cognitive functions (Oertel-Knöchel et al., 2013). 
Goldman and colleagues (2009) suggest that “predominant functional impairment of prefrontal 
and medial temporal structures in schizophrenia may not be exclusively due to localized 
structural-functional effects, but also mediated through the extensive interconnections that these 
regions maintain with the rest of the brain”. It is also possible that tasks with high cognitive load 
will cause the recruitment of more brain regions in individuals with schizophrenia. That is, the 
more cognitively demanding the task, the more the brain of those with schizophrenia may 
compensate to overcome abnormal neurodevelopment and possible progressive brain 
abnormalities of the disease (Ehrlich et al., 2012).  
Smoking and Schizophrenia 
There has been considerable interest in targeting cognitive deficits in schizophrenia given 
that these deficits are strong predictors of functional outcome (Green, Kern, & Heaton, 2004; 
Heinrichs, Goldberg, Miles & McDermid Vaz, 2008). The effects of nicotine have gained 
significant attention following reports linking nicotine to increased activity in an otherwise 
hypoactive prefrontal area, which may activate the dopaminergic reward system and affect 
motivation and other negative symptoms of the disorder (Glassman, 1993; Šagud, Mihaljević-
Peleš, Mück-Šeler, Pivac, Vuksan-Ćusa, Brataljenović, & Jakovljević, 2009). Furthermore, 
nicotine consumption among patients has also been credited for possibly reducing drug side 
effects and enhancing cognitive performance in patients (Glassman, 1993; Šagud et al., 2009; 
Winterer, 2010).  
Smoking prevalence within the schizophrenia population is approximately 2-3 times that 
of the general population (Goldberg & Van exan, 2008; Mitchell & Dahlgren, 1986; Üçok, Polat, 
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Bozkurt, & Meteris, 2004) with rates as high as approximately 90% (de Leon & Diaz, 2005; 
Strand & Nybäck, 2005; Ücok et al., 2004), and is also the highest among clinical populations 
(Kalman, Morissette, & George, 2005). While cigarette consumption may have some so-called 
‘benefits’ for individuals with schizophrenia, such benefits come at a tremendous cost given the 
increased health risks of lung cancer, cardiovascular disease, and associated mortality risks 
(Baliunas, Patra, Rehm, Popova, & Taylor, 2007; Wildgust, & Beary, 2010). In fact, smoking-
related acute care resulted in a total cost of 2.5 billion dollars in Canada in 1 year alone (Baliunas 
et al., 2007). 
Nonetheless, research evidence suggests that when compared to nonpsychiatric controls, 
individuals with schizophrenia smoke cigarettes that contain higher levels of nicotine, and also 
extract more nicotine from each cigarette smoked causing higher nicotine blood levels (Olincy, 
Young, & Freedman, 1997; Strand & Nyback, 2005). However, studies have found diminished 
concentration of nicotinic receptors in postmortem brains of individuals with schizophrenia than 
in nonpsychiatric controls (Breese, Lee, Adams, Sullivan, Logel, Gillen, Marks, Collins & 
Leonard, 2000; Marutle, Zhang, Court, Piggot, Johnson, Perry, Perry & Nordberg, 2001). 
Additionally, nicotinic receptors are not upregulated in smokers with schizophrenia following 
consumption of nicotine unlike in controls, (Breese et al., 2000). Using an animal model analog, 
Breese et al. (2000) also found evidence to support an upregulation of nicotinic receptors in rats 
even with chronic psychotropic treatment. Thus, there appears to be some differences between 
patients and controls not only in smoking behaviour, but also potential differential 
neurobiological mechanisms of action of nicotine dependent on psychiatric status. 
Nicotine’s supposed benefits for patients have led to the self-medication hypothesis. That 
is, individuals with schizophrenia smoke to improve the negative symptoms of the disorder (such 
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as apathy), alleviate side effects associated with psychotropic medications, and also improve 
cognitive deficits (for reviews see Kumari, 2005; Winterer, 2010; Freedman, 2014). However, 
the self-medication hypothesis is not without its criticisms as evidence emerged of the potential 
role of the tobacco industry in research funding, biasing publications, as well as lending support 
to deter the prohibition of smoking in psychiatric settings (Prochaska, Hall, & Bero, 2008).  
Notwithstanding, nicotine has been suggested to enhance such cognitive functions as 
memory and attention in nonsmokers and nicotine-deprived and non-deprived smokers (see 
Heishman, Kleykamp, & Singleton, 2010 for meta-analysis and Jasinska, Zorick, Brody, & 
Stein, 2014 for a review). It follows, therefore, that given the smoking prevalence in the 
schizophrenia population, studies continue to emerge examining the possible role of nicotine on 
cognition. Research interest in nicotine and the self-medication hypothesis in schizophrenia may 
possibly be due to the importance of cognitive functioning for day-to-day functioning and need 
for targeted treatment.  
The evidence suggests that nicotine consumption may improve cognitive deficits since 
individuals with schizophrenia who smoke outperform nonsmoking patients on measures of 
sensory gating (Dalack, Healy, & Meador-Woodruff, 1998; George, Termine, Sacco, Allen, 
Reutenauer, Vessicchio, & Duncan, 2006; Hong, Wonodi, Lewis, & Thaker, 2007; Kumari, 
Soni, & Sharma, 2001; Swerdlow, Light, Cadenhead, Sprock, Hsieh, & Braff, 2006), selective 
and sustained attention (George et al., 2002; Sacco et al., 2005), and working memory (reviewed 
in Freedman, 2014). Furthermore, patients who have no previous history of smoking have 
reported to be at a greater disadvantage than former or current smokers with schizophrenia on 
neurocognitive tests of sustained attention, processing speed, and response inhibition (Wing, 
Bacher, Sacco & George, 2011). 
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Thus far, findings support the notion that nicotine consumption temporarily improves 
performance on such cognitive tasks as working memory and selective attention. Neuroimaging 
studies also found that patients who smoke show greater activation in brain areas important for 
optimal performance of these tasks than patients who do not smoke (e.g., thalamus, anterior 
cingulate, and frontal cortex; Jacobsen, D’Souza, Mencl, Pugh, Skudlarski, & Krystal, 2004; 
McClernon, 2009). Furthermore, Tregellas and colleagues (2007) found that patients who smoke 
have greater gray matter volume in certain disease-related brain areas compared to non-smoking 
patients. Specifically, gray matter volumes among patients who smoked were greater in the 
dorsolateral prefrontal cortex, superior temporal gyrus, orbitofrontal cortex, medial frontal gyrus, 
and insula in comparison to nonsmoking patients (Tregellas et al., 2007; McClernon, 2009). 
Reduced gray matter in these particular areas among patients have been linked to deficits in 
working memory (dorsolateral prefrontal cortex), integration of sensory information with 
internal states (insula), the presence of positive symptoms such as hallucinations and thought 
disorder (superior temporal gyrus) and social cognition (medial frontal gyrus and orbitofrontal 
cortex; Tregellas et al., 2007). Although patient smokers had more gray matter in disease-related 
areas their volumes were not comparable to that of controls (Tregellas et al., 2007).  
There is mixed evidence, however, that patient smokers (particularly chronic smokers) 
show disruptions in functional-connectivity networks (Jasinska et al., 2014). Furthermore, 
current research findings not only suggest that acute nicotine has limited clinical benefit for 
patients as compared to controls (Hahn, Harvey, Concheiro-Guisan, Huestis, Holcomb, & Gold 
2013), but also that chronic nicotine exposure may be responsible for cognitive impairments 
(Counotte, Goriounova, Li, Loos, Van Der Schors, Schetters, Schoffelmeer, Smit, Mansvelder, 
Pattij, & Spijker, 2011). Smokers with no psychiatric history have also been found to have 
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poorer performance on cognitive measures (e.g., working memory and sustained attention), 
reduced activity and gray matter volume in certain brain areas when compared to nonsmoking 
controls (Ernst, Heishman, Spurgeon & London, 2001; Rusted, Caulfield, King & Good, 2000; 
Lawrence, Ross & Stein, 2002; Jasinska et al., 2014).  
There are also findings of cortical thinning amongst nonpsychiatric control smokers in 
several brain regions including the lateral prefrontal cortices, orbitofrontal cortex, and anterior 
cingulate, regions involved in working memory, sustained attention, decision-making, 
motivation, and arousal (Brody, Mandelkern, Jarvik, Lee, Smith, Huang, Bota, Bartzokis & 
London, 2004; Gallinat, Meisenzahl, Jacobsen, Kalus, Bierbrauer, Kiensat, Witthaus, Leopold, 
Seifert, Schubert & Staedtgen, 2006). There is further evidence to suggest that cigarette smoking 
has no effect on cognitive performance in nonsmoking controls (Wing et al., 2011).  
Current Study  
Evidently, additional research is needed to elucidate the relationship between smoking, 
cognition, and brain structure. To date, the relationship between psychopathology and smoking 
on cognitive performance and neural substrates remains unclear. Since smoking status is seldom 
controlled for in cognitive research outside of studies examining the effects of nicotine, 
understanding the contribution of nicotine dependence is a potentially important issue for data 
interpretation. Additionally, an examination of the illness-specific cognitive processes, rather 
than general cognition, is beneficial given the consensus that these processes are potentially 
modifiable by treatment and are strong predictors of functional outcome (Green, Kern, & 
Heaton, 2004; Heinrichs, Goldberg, Miles & McDermid Vaz, 2008; Nuechterlein, Barch, Gold, 
Goldberg, Green, & Heaton, 2004).  
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Indeed, patients tend to show similar impairments on both measures of crystallized 
intelligence (as indexed by intelligence quotient, IQ) and specific cognitive abilities (as 
measured by neurocognitive test batteries; e.g., processing speed, verbal memory, attention; 
Reichenberg & Harvey, 2007). However, estimates of IQ and neurocognitive tests that measure 
specific cognitive processes are independent measures of cognitive abilities (Reichenberg & 
Harvey, 2007), and it has been suggested that only specific cognitive processes can be potentially 
improved by treatment (Nuechterlein et al., 2004).  
To address the gap in the literature, therefore, the current study investigated smoking 
status as it relates to both specific cognitive processes and cortical thickness in individuals with 
schizophrenia and IQ-matched nonpsychiatric controls. Specifically, the study’s aim was to 
examine whether or not smoking status had a differential association with illness-specific 
cognitive processes and regional cortical thickness in smoking and nonsmoking patients and 
controls.  
Since patients on average tend to perform 1 standard deviation (SD) below that of healthy 
controls on several neurocognitive measures (reviewed in Dickinson & Harvey, 2009), it was 
predicted that there would be a main effect of psychiatric status (patient vs. control) such that IQ-
matched controls would outperform patients on all measures of specific cognitive abilities. It was 
further hypothesized that there would be a main effect of smoking status whereby nonsmokers 
would demonstrate better performance on cognitive tasks than smokers. This hypothesis was 
developed based on previous findings that it is rather acute nicotine consumption that may 
enhance cognitive performance (Jasinska et al., 2014), and the present research study did not 
examine the immediate effects of nicotine on cognitive performance.  
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Lastly, an interaction effect was anticipated such that poorer performance was expected 
with the presence of psychiatric illness and being a smoker, with the greatest impairment 
expected with psychiatric illness. Therefore, patient smokers were expected to have the poorest 
performance on cognitive tasks than the other groups (patient nonsmokers, control smokers, and 
control nonsmokers), and control nonsmokers were expected to have best performance. Control 
smokers were hypothesized to outperform patient nonsmokers. It was also examined whether or 
not psychiatric and smoking status may similarly relate to cortical thickness as with cognitive 
functioning. The study design may thus address whether or not there is a relationship between 
both psychiatric and smoking status on cognitive performance and neural substrates as indexed 
by cortical thickness.  
Method 
Participants 
Individuals with schizophrenia or schizoaffective disorder were recruited from outpatient 
mental health clinics and services within Hamilton, Ontario. These services include: Cleghorn 
Early Intervention in Psychosis Program (St. Joseph's Healthcare Hamilton), Community 
Schizophrenia Service (St. Joseph's Healthcare Hamilton), Hamilton Program for Schizophrenia, 
Schizophrenia Society of Canada (Hamilton Chapter), and Path for Employment Services. 
Controls were recruited from the Hamilton region through advertisements on Kijiji, posted 
flyers, and word-of-mouth. 
Inclusion criteria were limited to male and female participants between 18-65 years old 
who were fluent in English and had normal or corrected vision. Furthermore, individuals were 
screened to ensure they did not have any past or existing neurological or endocrine condition 
(e.g., epilepsy, head trauma, or Cushing’s disease, etc.), developmental disability, or substance 
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abuse (according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition 
(DSM-IV; American Psychiatric Association, 2000). Healthy control participants were excluded 
if they reported a diagnosed psychiatric illness within the past 6 months. Diagnosis was 
confirmed for patients using the Structured Clinical Interview for DSM-IV Axis I Disorder-
Patient Edition (SCID; First et al., 1996) prior to testing. This research study was approved by 
the institutional research ethics board at York University and St. Joseph’s Healthcare Hamilton. 
All participants provided written informed consent and were compensated for their participation.  
Following eligibility requirements, a total of 71 patients (43 males and 28 females) and 
63 controls (39 males and 24 females) participated in the study. Patient charts confirmed that all 
patients were taking antipsychotic medications. Patient and control groups comprised of 
individuals between 18 and 65 years of age (patients had a mean age of 41.49, SD = 10.29, and 
control participants had a mean age of 39.27, SD = 11.85). The average time since first onset of 
characteristic signs and symptoms of the illness reported for patient nonsmokers was 17.67 (SD 
= 9.4) and 16.71 (SD = 12.5) for patient smokers, which was not significantly different.  
Smoking Status 
 Thirty patients and 24 controls were smokers and 41 patients and 39 controls were 
nonsmokers. Smoking status was assessed using self-reports of number of cigarettes smoked 
daily. Upon commencing the study, participants were not provided with time during the session 
for tobacco consumption.  
Clinical Measures 
Patients’ current symptom severity was measured using the Positive and Negative 
Syndrome Scale (PANSS; Opler, Kay, Lindenmayer, & Fiszbein, 1999), a semi-structured 
interview which contains subscales to examine positive, negative, and general psychopathology 
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symptoms commonly found among those with the disorder. The positive scale captures 
symptoms present among individuals with schizophrenia not usually found among the general 
population such as hallucinations, delusions, grandiosity, persecutory ideation, and conceptual 
disorganization. The negative scale assesses the absence of normative features found among 
healthy individuals, which include social and emotional withdrawal, rigidity of attitudes and 
beliefs, poor rapport and blunted affect. Lastly, the general psychopathology scale evaluates 
overall illness severity encompassing abnormal mannerisms, bizarre thought content, disturbance 
of volition, somatic preoccupation, disorientation and insight, guilt, depression, anxiety and 
tension. PANSS is a 30-item measure assesses symptom severity using a 7-point Likert rating 
scale ranging from the absence of symptoms to the presence of extreme pathological symptoms. 
PANSS has proven internal reliability and homogeneity among the items (.73 to .83, p <.001), 
test-retest reliability where testing intervals are between 3-6 months, and high construct validity 
supporting the Positive, Negative, and General Psychopathology scales as mutually exclusive 
dimensions (Kay, Fiszbein, & Opler, 1987). 
Neurocognitive Measures 
Participants’ verbal and non-verbal abilities were measured using the Vocabulary and 
Matrix Reasoning subtests of the Wechsler Abbreviation Scale of Intelligence (WASI; Wechsler, 
1997) respectively, and are robust estimates of general intelligence (or intelligence quotient (IQ); 
Alwin & McCammon, 2001). Verbal ability tends to be less susceptible to psychiatric illness 
such as schizophrenia and is supposed to be a measure of crystallized intelligence (Sheppard, & 
Vernon, 2008). The Reading subtest of the Wide Range Achievement Test (WRAT-4) is also a 
measure of verbal ability, and is linked to premorbid functioning (Wilkinson & Robertson, 
2006).  
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 Cognitive function was also measured using the MATRICS (Measurement and Treatment 
Research to Improve Cognition in Schizophrenia) Consensus Cognitive Battery (MCCB; 
Nuechterlein et al., 2008), which is a battery of tests developed by experts that is sensitive to the 
impairments commonly found among individuals with schizophrenia that can be targeted for 
treatment (August, Kiwanuka, McMahon, & Gold, 2012). The battery of tests include measures 
of processing speed (Category fluency, Symbol coding, Trail Making A), attention/vigilance 
(Continuous Performance Test, Identical Pairs [CPT-IP]), working memory (Letter-Number 
Sequencing [WAIS-III], Spatial Span [Wechsler Memory Scale III]), verbal learning (Hopkins 
Verbal Learning Test-Revised), visual learning (Brief Visuospatial Memory Test-Revised), 
reasoning and problem solving (Mazes (Neuropsychological Assessment Battery [NAB]), and 
social cognition (Mayer-Salovey-Caruso Emotional Intelligence Test [MSCEIT]). Social 
cognitive functioning was also independently measured using the Reading the Mind in the Eyes 
and the Faux Pas Theory of Mind test (ToM; Baron-Cohen et al., 1997; Stone et al., 1998). 
Neuroimaging 
Imaging was conducted at the Brain Imaging Research Centre, Brain-Body Institute, St. 
Joseph’s Healthcare Hamilton. Data were gathered from a high-resolution 3-Tesla GE HD Signa 
MR whole body short bore scanner (General Electric, Milwaukee, WI), with an 8-channel 
parallel receiver head coil (Invivo Corporation, Gainesville, FL).  A T1-weighted axial 
anatomical scan was acquired using a three-dimensional fast spoiled gradient echo sequence with 
inversion recovery preparation.  The anatomical image had 152 slices (2 mm thick with 1 mm 
overlap) with the following imaging parameters: time to repetition (TR)/ echo time (TE) = 
7.5/2.1 ms, TI = 450 ms, field of view (FOV) = 24 cm, matrix = 512 x 512, flip angle = 12ᵒ, 
receiver bandwidth (rBW) = +/-62.5 kHz, and number of excitations (NEX) = 1.  
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Testing Sessions 
Testing took place in Hamilton, Ontario where participants were recruited. Individuals 
with schizophrenia participated in 4 sessions on separate days. In the first session, participants 
were administered the SCID, PANSS, and WASI, which lasted no more than 3 hours in duration. 
The second session consisted of the cognitive batteries and the additional measure of verbal 
ability (MCCB and WRAT, respectively) and took approximately 2.5 -3 hours to complete. 
Social cognition was assessed in the third session (1.5 hours to complete), and imaging 
completed in the last session (with a duration of 20 minutes). Controls participated in 3 sessions 
given that diagnosis and symptom severity did not need to be assessed with the SCID and 
PANSS. Thus, control participants were administered the measures of cognition, verbal and non-
verbal abilities (MCCB, WASI, and WRAT) in the first session with an average time to 
completion of approximately 2.5 hours. In the second session, social cognition was assessed and 
completed in 1.5 hours. Lastly, imaging data was collected in the third and final session and had 
a total duration of approximately 20 minutes.  
Statistical Analyses 
 Neurocognitive behavioural data was analyzed using the Statistical Package for the 
Social Sciences 21 (SPSS). A two-way analysis of variance was conducted with both psychiatric 
and smoking status as independent variables and cognitive performance as the dependent 
variable; differences with a p value less than 0.05 were considered significant. Post hoc t tests 
were used for significant interactions using the Bonferonni-adjusted p. Lastly, chi-squared 
analysis was used to measure the difference between group frequencies for such categorical 
variables as sex, handedness and first language spoken. 
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The T1-weighted images collected for each participant were pre-processed in order to 
segment the brain and to align cortical structures across the subjects using FreeSurfer image 
analysis (http://surfer.nmr.mgh.harvard.edu/). Cortical thickness was defined as the distance 
between pial surface to the gray/white matter border at each vertex. Surface maps were smoothed 
with a 15 mm full-width-half-maximum Gaussian kernel. A main effect of psychiatric status was 
examined using ANCOVA with sex and age as covariates and cortical thickness as the dependent 
variable. Similarly, ANCOVA was conducted to examine a main effect of smoking status using 
sex and age again as covariates. I further examined whether or not there was an interaction 
between smoking status and psychiatric status on cortical thickness. A t value of 3.5 was used as 
the cut-off for significance such that only brain regions that had values of 3.5 or greater were 
considered for interpretation, with a p value less than 0.05. 
Results 
Demographic Characteristics and Clinical Profile 
Demographic profiles comparing smoking and nonsmoking individuals with 
schizophrenia and nonpsychiatric controls can be found in Table 1. When comparing the four 
experimental groups (patient nonsmokers, patient smokers, control nonsmokers and control 
smokers), there was no significant difference in age, sex, handedness, or first language learned. 
Group compositions were such that the majority of participants were right-handed males who 
spoke English as their first language. However, there was a significant main effect of years of 
education obtained. Post hoc analysis revealed that years of education obtained was significantly 
different when comparing control smokers to both patients and controls who were nonsmokers 
such that control smokers had fewer years of schooling, p = 0.001. No other group differences 
were observed for this variable. 
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There was no significant difference with respect to the frequency of smoking per day 
between patients and controls (see Table 1). Lastly, symptom severity was examined between 
patient nonsmokers and patient smokers using PANSS and there were no significant group 
differences on any subscales (see Table 2). This suggests that the clinical profiles of the patient 
groups were indistinguishable. 
Performance on Neurocognitive Measures 
 A two-way ANOVA revealed no main effect of psychiatric status on estimates of IQ and 
premorbid functioning (i.e., WASI and WRAT-4, respectively; refer to Table 4); that is, there 
was no significant difference between individuals with schizophrenia and healthy controls on 
these measures. However, there was a main effect of smoking status on both the WASI 
(measuring verbal and non-verbal abilities; p < 0.001) and WRAT (an independent measure of 
verbal ability; p < 0.001). Here, smokers scored significantly lower than nonsmokers. On all 
other measures of specific cognitive abilities using the MCCB (i.e., processing speed, attention/ 
vigilance, working memory, verbal learning, visual learning, reasoning and problem-solving, and 
social cognition) and independent measures of social cognition a two-way ANOVA confirmed a 
main effect of psychiatric status, a main effect of smoking status, and an interaction between 
both independent variables and the reasoning and problem-solving subscale of the MCCB (see 
Table 3). 
 Specifically, examining MCCB cognitive domain scores, the main effect of psychiatric 
status revealed that patients had slower speed of processing than controls (p < 0.001) and 
demonstrated diminished attention (p = 0.008).  Patients also scored lower on tests of working 
memory (p = 0.016), verbal learning (p < 0.001), visual learning (p = 0.002), reasoning and 
problem solving (p < 0.001), and social cognition (p = 0.017). The MCCB composite score is an 
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overall score, which is comprised of all other domain scores. Here, the composite score similarly 
reveals that patients were significantly outperformed by controls (p < 0.001). With respect to the 
additional measures of social cognition, patients were less able to detect faux pas in the social 
situations presented (p = 0.001) and emotional expression as captured by the Reading the Mind 
in the Eyes task, (p = 0.001). 
 Similarly, the main effect of smoking status revealed that nonsmokers’ scores 
significantly exceeded that of smokers on all but the MCCB’s measure of social cognition. In 
fact, smokers had significantly lower scores on measures of attention (p = 0.036), processing 
speed (p < 0.001), working memory (p = 0.002), verbal and visual learning (p < 0.001 and p = 
0.008, respectively), reasoning and problem solving (p = 0.040). Smokers also had an overall 
lower MCCB composite score when compared to nonsmokers. Although the MCCB measure of 
social cognition was not significant, the two independent measures of social cognition (faux pas 
and reading the mind in the eyes) revealed significant differences between smokers and 
nonsmokers, with nonsmokers again having higher scores than smokers (faux pas, p = 0.043 and 
reading the mind in the eyes p < 0.001). 
 There was a significant interaction between smoking status and psychiatric status on the 
reasoning and problem solving task, p = 0.003. Post hoc analysis revealed that control 
nonsmokers (M = 53.46, SD = 9.20) had superior reasoning and problem solving scores when 
compared to patient smoker (M = 42.17, SD = 9.67), patient nonsmoker (M = 40.71, SD = 9.27) 
and control smoker (M = 45.33, SD = 7.55), (p < 0.001). No other significance differences were 
found.  
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Neuroimaging Data 
 The ANCOVA revealed a main effect of psychiatric status on cortical thickness such that 
there was widespread cortical thinning in patients (Figures 1 and 2). For example, in the right 
hemisphere, cortical thickness reductions in patients were observed in the superior frontal gyrus 
(t = -3.69), superior and inferior parietal gyri (t = -3.75 and (t = -5.81, respectively), and insula (t 
= -5.35). Individuals with schizophrenia also had greater reductions in the left hemisphere in the 
following regions: precentral and postcentral gyri (t = -3.56 and t = -5.89, respectively), superior 
temporal gyrus (t = -4.22) and fusiform (t = -5.19). Lastly, there was significant reduction in 
cortical thickness found bilaterally in the precuneus (left hemisphere, t = -6.29 and right 
hemisphere, t = -4.94). 
 It was further examined whether or not there was a main effect of smoking status on 
cortical thickness and found no significant reductions in the left hemisphere. However, there was 
a significant main effect found in the right hemisphere such that nonsmokers had greater 
thickness than smokers in the middle temporal gyrus (t = 5.32) and banks of the superior 
temporal sulcus (t = 3.66), see Figure 3. The inferior temporal gyrus was marginally significant (t 
= 3.24). 
 Lastly, a significant interaction was found between smoking status and psychiatric status 
(refer to Figure 4). Patient smokers and control nonsmokers had greater cortical thickness in the 
left parahippocampal gyrus (t = 4.04), and bilateral medial orbitofrontal gyri (left hemisphere t = 
3.89 and right hemisphere t = 4.19) than patient nonsmokers and control smokers.  
Discussion 
 Cognitive impairments are a core feature of schizophrenia that significantly impact 
quality of life. Although there is considerable research in this area aimed at better understanding 
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the neural mechanisms of illness-specific cognitive functions to target for treatment, they are not 
well understood. Furthermore, mixed findings of nicotine’s effect on cognition suggest that 
further research is needed to better understand the relationship between smoking status and the 
pathophysiology of schizophrenia (Brody et al., 2004; Ernst et al., 2001; Tregellas et al., 2007).  
The goal of the current study was to examine the effect of smoking status on the 
potentially modifiable treatment relevant cognitive processes and on regional cortical thickness 
among individuals with schizophrenia and nonpsychiatric controls. Although studies tend to 
report findings of lower IQ among individuals with schizophrenia as compared to nonpsychiatric 
controls, patients and controls were matched on this variable in the current study.  
It was not surprising that verbal ability (as measured by the WRAT) was not significantly 
different between the two groups given previous findings that verbal ability remains relatively 
intact among those with schizophrenia and is less affected by the illness (Heinrichs & Zakzanis, 
1998). Given that patients’ verbal ability and general intelligence matched that of controls our 
data provides an opportunity to detect the effects of smoking status and diagnosis on specific 
cognitive abilities and cortical thickness. 
 Using a battery of neurocognitive tests specifically designed to capture potentially 
modifiable cognitive processes vulnerable to schizophrenia, I replicated previous findings that 
patients have impairments in attention, working memory, processing speed, verbal and visual 
learning, social cognition, and reasoning and problem solving in comparison to controls. These 
deficits have been consistently shown and have led to the recognition that deficits in cognition 
are characteristic of the illness (see Heinrichs & Zakanis, 1998; Dickinson & Harvey, 2009; and 
Winterer, 2010 for reviews). Widespread reduction in cortical thickness was also observed in 
patients as compared to controls in areas previously found to be implicated in the 
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pathophysiology of the disorder and the corresponding cognitive deficits (i.e., superior frontal, 
superior temporal, inferior parietal, precuneus, insula, and fusiform; Ehrlich et al., 2012; Fossati 
et al., 1999; Goldman et al., 2009; Mjellem & Kringlen, 2001, Nestor et al., 2007; Onitsuka, 
Shenton, Salisbury, Dickey, Kasai, Toner, Frumin, Kikinis, Jolesz & McMarley, 2004; Pearlson 
& Marsh, 1999; Tregellas et al., 2007).  
 Examining the relationship between smoking status and measures of general intelligence 
revealed that smokers were more likely to have lower general intelligence than nonsmokers. 
Smokers also tended to have greater deficits on all neurocognitive measures (i.e., speed of 
processing, attention, working memory, visual and verbal learning, reasoning and problem 
solving, and independent measures of social cognition). These findings are in line with previous 
reports that smoking impairs cognition (Brody et al., 2004; Ernst et al., 2001; Gallinat et al., 
2006). It may be that individuals with characteristics such as lower general intelligence may have 
less support in their quitting attempts and thus may be less successful despite the possible link 
between smoking and impaired cognitive functioning (and consequently, day-to-day functioning; 
Kotz & West, 2009). 
Neuroimaging results revealed that nonsmokers had greater cortical thickness than 
smokers in the inferior and middle temporal gyri as well as the banks of the superior temporal 
sulcus of the right hemisphere. These areas are involved in semantic memory and language 
processing (inferior and middle temporal gyrus; Nestor et al., 2007) and integration of visual, 
auditory and somatosensory information as well as face processing (banks of the superior 
temporal sulcus; Seltzer & Pandya, 1978). It is important to note that the inferior temporal area 
was only marginally significant. 
 
 
  
25 
 The main purpose of this study was to examine the relationship between smoking status, 
cognition, and cortical thickness in both patients and controls. The sole interaction effect found 
in the behavioural data was on measures of reasoning and problem solving where control 
nonsmokers outperformed control smokers, patient smokers and patient nonsmokers. 
Interestingly, control smokers were indistinguishable from both patient groups suggesting that 
they had impaired reasoning and problem solving abilities. It has been suggested that those who 
abstain from smoking for approximately 3 hours can induce nicotine-withdrawal symptoms, 
which may affect cognitive performance (see Sacco, Bannon & George, 2004). In our study, the 
neurocognitive battery administered had a duration of approximately 2-3 hours, and participants 
were not given smoke breaks. However, Bell et al. (1999) found that nicotine-deprivation in 
smokers did not affect performance on a logical reasoning task. Therefore, these results cannot 
be attributed to nicotine-deprivation. 
 Problem solving skills are crucial for functional capacity in daily living. In fact, among 
people with schizophrenia, problem solving abilities are highly correlated with other cognitive 
functions (e.g., processing speed, working memory, and verbal memory), negative symptoms 
(e.g., flat affect and emotional withdrawal), and functional outcome (Revheim, Schechter, Kim, 
Silipo, Allingham, Butler & Javitt, 2006). Indeed, inpatients demonstrate significantly lower 
problem solving skills than outpatients (Revheim et al., 2006). It is understandable that these 
variables may correlate and affect overall functioning, as activities of daily living require 
attention to social cues, reasoning and problem solving skills, and efficient processing of 
information.  
Research examining the effects of nicotine on cognition has relied to some extent on 
contrasting both smoker and nonsmoker patients to nonsmoking controls, which will inevitably 
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allow for larger effects. However, the greater issue may lie in cognitive research where smoking 
status is not measured. That is, if nicotine consumption alters information processing and 
possibly the neural pathways involved, failure to assess smoking status may impede data 
interpretation in general, and in understanding illness-specific impairments and the 
pathophysiology of schizophrenia. Our findings suggest that it is especially important to take into 
consideration smoking status when collecting neuroimaging data given the distinct differences in 
cortical thickness as a function of both illness and smoking status.  
Indeed, patient smokers and control nonsmokers had similar patterns of cortical thickness 
in the left parahippocampal gyrus and bilateral medial orbitofrontal gyrus. The parahippocampal 
gyrus is important for integrating sensory information and the processing of communication cues 
(McDonald, Highley, Walker, Herron, Cooper, Esiri, & Crow, 2000) while the medial 
orbitofrontal gyrus is involved in decision-making and emotional perspective-taking (Elliott, 
Dolan, & Frith, 2000; Hynes, Baird & Grafton, 2006). The neuroimaging results, therefore, 
suggest smoking status is differentially correlated with cortical thickness patterns among patients 
and controls. These particular areas where patient smokers and control nonsmokers have similar 
neurobiological profiles seem to be especially important for executive functions and social 
cognition. Here, the data also lend support for the interconnectedness of various brain regions 
involved in the pathophysiology of schizophrenia. Thus, it may well be that impairments result 
from faulty connections (Goldman et al., 2009; Oertel-Knochel et al., 2013).  
Taken together, our data suggest that smoking status and schizophrenia are both 
independently correlated with cognition and brain structure. These results have serious 
implications as failure to take into account smoking status in cognitive research may explain 
some of the variability in schizophrenia research. In particular, smoking prevalence among the 
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schizophrenia population tends to be 2-3 times that of the general population (Goldberg & Van 
Exan, 2008), which may further obscure results if smoking status is not assessed. 
Limitations 
The behavioural neurocognitive data do not lend support for nicotine enhancement of 
cognitive deficits within the patient group as previously found in the literature. However, studies 
have found that it is the acute consumption of nicotine or nicotinic agents that may improve 
performance on cognitive measures, and impairments or a lack of effect are seen when smokers 
(particularly psychiatric participants) abstain and perform cognitive tasks (George et al., 2002; 
Sacco, Bannon & George, 2004). Thus, it is worth noting that the current study examined the 
relationship between smoking status (i.e., whether or not an individual smokes) and not the acute 
consumption of nicotine. While it may be argued that a limitation of the present study is that it 
did not assess cognition in smokers following tobacco consumption, the goal of the study was to 
examine the effect of smoking status on cognitive performance and brain structure. Given that 
cognitive studies do not commonly assess smoking status of participants, our findings provide 
support for its inclusion as a variable of interest as it is independently correlated with both 
neurocognitive performance and neuroimaging results. 
 Another limitation of the study is the concern of generalizability given that the patient 
sample did not show lower general intelligence when compared to controls, which would 
normally be expected from random sampling. Indeed, patients tend to demonstrate poorer 
performance on neurocognitive measures (reviewed in Dickinson & Harvey, 2009). However, 
that patients and controls were matched on general intelligence and had similar educational 
attainment allowed for better comparison of specific cognitive abilities and regional cortical 
thickness between the groups.  
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Additionally, patient smokers tend to have reduced negative symptoms compared to 
patient nonsmokers as measured by lower overall PANSS score (Zhang, Liang, Chen, Xiu, He, 
Cheng, Wu, Yang, Haile, Sun, Lu, Kosten & Kosten, 2012). However, in the current study 
clinical profiles of patient smokers and patient nonsmokers were not significantly different. 
Given that analyses of smoking status would include data from both patient and control groups, 
this finding is beneficial for interpreting the current findings. That is, if patient smokers were 
significantly less symptomatic than patient nonsmokers the results of the neurocognitive 
measures may have been skewed as symptom severity is highly correlated with cognitive 
functioning (such as, problem solving; Revheim et al., 2006). 
Conclusion 
Cognitive impairments are well documented among the schizophrenia population and are 
predictive of functional outcome. There has been some support for the self-medication 
hypothesis that nicotine enhances cognitive performance among individuals with schizophrenia 
in the extant literature. The higher prevalence of smoking in this clinical population has been 
suggested as an attempt by patients to counteract illness-specific cognitive impairments and 
psychotropic medication side effects. However, there are inconsistencies in the literature with 
respect to the effect of nicotine on cognition and structural brain changes in both people with 
schizophrenia and nonpsychiatric controls. Whether nicotine enhances or impairs cognitive 
performance, smoking status should be seriously considered in cognitive research to minimize 
confounds to data interpretation. 
The current data point to the importance of assessing smoking status in cognitive research 
in general as well as in schizophrenia research in particular. The goal is to understand the 
neuroanatomical abnormalities and their relationship to cognitive deficits as a function of the 
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illness separately from other confounds (such as tobacco consumption). Given the current 
findings, it follows that smoking status may be an artifact in the interpretation of cognitive 
research data. Thus, the use of schizophrenia control comparisons in the existing literature is of 
questionable value. Measuring smoking status is of great utility as future treatment may be more 
effective in targeting illness-specific deficits to possibly establish significant change in quality of 
life. 
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Appendices 
Appendix A 
Table 1 
Demographic Characteristics of Smoking and Nonsmoking Patients and Healthy Controls 
*** denotes main effect significance at p < 0.001 
Patients Controls 
 Nonsmoker Smoker Nonsmoker Smoker Test value 
Variable 
 
(n = 41) (n = 30) (n = 39) (n = 24)  
Age,  
Mean (SD) 
41.71 (10.56) 41.55 (10.31) 39.72 (13.09) 38.54 (9.74) F3,133 = 0.55 
Sex,  
Males (%) 
26 (63%) 17 (57%) 23 (59%) 16 (67%) χ2 = 0.87 
Handedness, 
Right (%) 
33 (81%) 25 (83%) 36 (92%) 19 (79%) χ2 = 0.57 
Eng 1st 
Lang., n (%) 
38 (93%) 27 (90%) 37 (95%) 22 (92%) χ2 = 0.89 
Education, 
Mean (SD) 
13.41 (2.44) 12.41 (1.84) 13.10 (2.00) 11.29 (2.33) F3,133 = 
5.44*** 
Smoke Freq., 
Mean (SD) 
N/A 17.04 (8.59) N/A 12.47 (8.35) t49 = 1.91 
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Appendix B 
Table 2 
Clinical Characteristics of Patient Nonsmokers and Patient Smokers 
† = t-scores 
no significant differences were found, p > 0.05 
 Patient Nonsmoker Patient Smoker Test value 
Variable (n = 41) (n = 30)  
    
PANSS Positive† 41.02 (7.52) 44.40 (8.27) t69 = -1.79 
    
PANSS Negative† 37.80 (6.82) 39.43 (7.06) t69 = -.98 
    
Composite T Scores† 53.12 (7.50) 54.13 (9.67) t69 = -0.50 
    
PANSS General† 40.02 (7.18) 43.10 (8.18) t69 = -1.68 
    
Anergia† 42.17 (9.44) 46.10 (10.40) t69 = -1.66 
    
Thought Disturbance† 40.24 (7.70) 43.43 (7.58) t69 = -1.74 
    
Activation† 44.15 (7.66) 44.03 (6.54) t69 = 0.07 
    
Paranoid† 44.02 (6.62) 44.10 (7.73) t69 = -0.04 
    
Depression† 50.56 (12.56) 52.27 (12.87) t69 = -.56 
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Appendix C 
Table 3 
MATRICS Consensus Cognitive Battery. Specific Cognitive Abilities of Patients vs. Healthy Controls and Smokers vs. Nonsmokers 
 
 PT 
(n = 71) 
CN 
(n = 63) 
Test statistic 
SM 
(n = 54) 
NS 
(n = 80) 
Test statistic 
MCCB       
Process. Speed 34.53 (10.95) 45.41 (12.73) F1,129 = 25.24*** 36.87 (12.20) 41.55 (13.22) F1,129 = 4.50* 
Attention 35.21 (13.19) 42.19 (14.23) F1,129 = 7.26** 34.36 (13.67) 41.28 (13.75) F1,129 = 8.20** 
Working Memory 38.16 (12.65) 43.60 (12.40) F1,129 = 6.00* 36.43 (12.60) 43.59 (12.15) F1,129 = 10.39** 
Verbal Learning 37.31 (9.73) 44.98 (10.35) F1,129 = 17.25*** 36.91 (8.91) 43.63 (11.00) F1,129 = 15.20*** 
Visual Learning 33.66 (11.74) 40.60 (10.65) F1,129 = 10.28** 33.74 (11.86) 39.08 (11.21) F1,129 = 7.34** 
Reason./ Prob Solv 41.31 (9.40) 50.37 (9.43) F1,129 = 24.46*** 43.60 (8.83) 46.93 (11.20) F1,129 = 4.29*# 
Social Cognition 39.63 (12.37) 45.24 (12.89) F1,129 = 5.89* 40.79 (12.88) 43.28 (12.87) F1,129 = 1.06 
COMPOSITE 29.39 (13.40) 41.22 (14.41) F1,129 = 21.47*** 29.98 (13.95) 38.31 (14.92) F1,129 = 11.71** 
 
Abbreviations: PT = Patient; CN = Control; SM = Smoker; NS = Nonsmoker 
***denotes main effect significance at p <.001; ** main effect significance at p < .01; * main effect significance at p < .05;  
# denotes interaction effect 
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Appendix D 
Table 4 
Cognitive Profile of Individuals with Schizophrenia vs. Healthy Controls and Smokers vs. Nonsmokers 
 PT 
(n = 71) 
CN 
(n = 63) 
Test statistic 
SM 
(n = 54) 
NS 
(n = 80) 
Test statistic 
       
WASI IQ 
Estimate 
96.66 (21.40) 101.24 (20.35) F1,130 = 0.73 89.22 (18.74) 105.29 (19.97) F1,130 = 22.58*** 
WRAT-4 
Reading 
91.47 (11.50) 95.27 (11.73) F1,127 = 2.44 88.17 (9.81) 96.78 (11.69) F1,127 = 19.46*** 
Faux Pas 38.52 (13.03) 46.40 (10.29) F1,129 = 11.97** 39.51 (13.57) 43.98 (11.35) F1,129 = 4.16* 
Reading 
the Mind in 
Eyes 
21.72 (5.19) 25.24 (5.34) F1,129 = 12.50** 21.25 (5.41) 24.76 (5.19) F1,129 = 14.63*** 
 
Abbreviations: PT = Patient; CN = Control; SM = Smoker; NS = Nonsmoker;  
***denotes main effect significance at p <.001; ** main effect significance at p < .01; * main effect significance at p < .05 
# denotes interaction effect 
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Appendix E 
 
Figure 1. Widespread Cortical Thinning in Right Hemisphere of Individuals with Schizophrenia 
vs. Healthy Controls. Blue areas indicate reduced thickness. 
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Appendix F 
 
Figure 2. Widespread Cortical Thinning in Left Hemisphere of Individuals with Schizophrenia 
vs. Healthy Controls. Blue areas indicate reduced thickness. 
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Appendix G 
 
Figure 3. Greater Cortical Thickness in Right Middle Temporal Gyrus and Banks of Superior 
Temporal Sulcus of Nonsmokers than in Smokers. Red areas indicate greater thickness. 
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Appendix H 
 
Figure 4. Interaction between Smoking Status and Psychiatric Status reveals Increased Cortical 
Thickness in Patient Smokers and Control Nonsmokers in Bilateral Medial Orbitofrontal Gyrus 
and Left Parahippocampal Gyrus. Red areas indicate greater thickness. 
 
 
 
